Search results
Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 months agoImunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript November 17, 2023 Operator: Good...
Tango terminates USP1 inhibitor programme
Clinical Trials Arena via Yahoo Finance· 2 weeks agoTango Therapeutics has terminated the development of its TNG348 programme after data emerged from the Phase I/II trial showing that the therapy may cause...
Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico
Zacks via Yahoo Finance· 9 months agoExelixis, Inc.’s EXEL efforts to develop its oncology pipeline took another step forward when it...
How Is Ovarian Cancer Treated?
Health via Yahoo News· 1 year agoSurgery is one of the most effective treatments for ovarian cancer. Other treatments may include chemotherapy, radiation therapy, and targeted therapies.
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 2 weeks agoDive Brief: AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a slate of...
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
Zacks via Yahoo Finance· 7 months agoMerck MRK reported adjusted earnings of $2.13 per share for third-quarter 2023, beating the Zacks...
4 Recent Advances in Breast Cancer Research You Should Know About
SheKnows via Yahoo News· 2 years agoEach October our newsfeeds, timelines and television screens blush pink as an annual reminder for...
Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View
Zacks via Yahoo Finance· 2 years agoMerck & Co., Inc. MRK reported third-quarter 2022 adjusted earnings of $1.85 per share, beating the...
Delphia starts up with $67M to make a new type of cancer drug
BioPharma Dive via Yahoo Finance· 1 month agoThe startup is developing medicines designed to overstress cellular pathways to the point tumor...
Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo
Zacks via Yahoo Finance· 2 years agoRoche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails....
